Nanomedicine News

RSS

Founder of Oxford Nanopore Technologies Named Entrepreneur of the Year by RSC

Professor Hagan Bayley, Professor of Chemical Biology at the University of Oxford, was named Entrepreneur of the Year by the Royal Society of Chemistry at last night’s Industry and Technology Forum Awards. The a...

From Oxford Nanopore Technologies Ltd 24 Apr 2009

New Powerful Tool for Monitoring Cell Cycle Procession

As with higher-level organisms, reproduction is among the primary biological imperatives of the cell. This process is regulated through a multi-stage cell cycle; the more rapidly this cycle proceeds, the more quickly division takes place.

23 Apr 2009

CEO of Genetic Immunity to Present at Nanomedicine Conference

Power of the Dream Ventures, Inc. (OTCBB: PWRV), Hungary's premier technology acquisition and development company, is pleased to present this Genetic Immunity release, based on a previously announced agreement whereb...

23 Apr 2009

New Data Highlighting Key Milestones in Development of Novel Non-Inflammatory Nanoemulsion Technology

NanoBio Corp. announced today that it will present compelling new data highlighting key milestones in the development of its novel non-inflammatory nanoemulsion adjuvant platform technology at the National Foundation for Infectious Diseases (NFID) conference, April 27-29.

23 Apr 2009

First Major Study of Media Coverage, Policy Debates and Public Perceptions about Nanotechnology

The first major study of media coverage, policy debates and public perceptions about nanotechnology is the focus of a new book co-authored by Professor Stuart Allan of Bournemouth University.

23 Apr 2009

Researchers Using Nanotechnology to Develop Low-Cost Disposable Blood-Testing Kits

Professor Peter Ashburn is leading a team of University researchers who are developing low-cost, disposable blood-testing kits that can be made available in GPs' surgeries.

23 Apr 2009

Nanoparticle that Transports Antitumor Genes Selectively to Cancer Cells

Cancer researchers have been exploring gene therapy as an experimental treatment to fight the deadly disease despite the obstacles that have surfaced along the way. A cross-European research team has now gained a foothold in this area by developing a nanoparticle that transports antitumor genes selectively to cancer cells.

23 Apr 2009

Report Examines the Biomedical Applications of Electroactive Polymer Actuators

Research and Markets has announced the addition of John Wiley and Sons Ltd's new report "Biomedical Applications of Electroactive Polymer Actuators" to their offering.

From Research and Markets 23 Apr 2009

Roche NimbleGen and Sigma-Aldrich Started Collaboration to Further ChIP-chip Research

Roche NimbleGen and Sigma-Aldrich (Nasdaq:SIAL) have started a collaboration to further chromatin immunoprecipitation-on-microarray (ChIP-chip) research by aligning their two complementary technologies, Roche NimbleGen's ChIP-chip high-density microarrays and GenomePlex by Sigma-Aldrich.

From Sigma Aldrich 23 Apr 2009

BioAlliance Pharma Presents Results on New Biotherapy at AACR Annual Meeting

BioAlliance Pharma SA (Paris:BIO), a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, has presented results on its new biotherapy, plasmid AMEP™, for metastatic melanoma treatment at the at the American Association for Cancer Research (AACR) 100th Annual Meeting, in Denver, April 18 to 22, 2009.

22 Apr 2009